Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2024-06-19 Capital/Financing Update
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis extends its contract with Atlas to secure financing for its business activities
Capital/Financing Update Classification · 98% confidence The document is explicitly titled as a "Press release" and announces the extension of a financing agreement involving convertible bonds (ORNANE) with an investment fund (Atlas). It details the terms of this financing, potential dilution, and updates on clinical programs. This type of announcement, focusing on a specific corporate action (financing/capital structure change) released via a press release, aligns best with the Capital/Financing Update category (CAP). While it discusses potential dilution, the core subject is securing financing, not a general capital change (SHA) or a formal regulatory filing like a 10-K or IR. It is not a general regulatory filing (RNS) because it fits a more specific category (CAP). It is not an Earnings Release (ER) as it focuses on financing, not periodic financial results.
2024-06-19 English
Biophytis prolonge son contrat avec Atlas pour sécuriser le financement de ses activités
Share Issue/Capital Change Classification · 99% confidence The document is titled as a press release ("Communiqué de presse") announcing the renewal of a financing agreement involving the issuance of convertible bonds (ORNANE) with Atlas. This transaction directly relates to securing funding for the company's operations and clinical programs. This falls under the category of updates on company fundraising or capital structure changes. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER: Not an earnings release; it's a financing announcement. - CAP (Capital/Financing Update): This definition perfectly matches the content, which details a financing agreement extension involving convertible debt (ORNANE) up to 16 million euros. - RPA/RNS: While it is a press release, the core subject matter is a specific financing event, making 'CAP' more precise than the general 'RPA' or 'RNS' fallback.
2024-06-19 French
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press release" and announces a specific operational milestone: the successful industrial transfer of BIO101 production by a service provider (Seqens). This type of announcement, detailing progress in drug development, manufacturing, or clinical trials, is typically classified as a general corporate update or regulatory filing, rather than a formal financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a press release announcing a significant operational event and does not fit neatly into the specific categories like ER (Earnings Release), CAP (Financing), or LTR (Legal), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory/corporate announcements not covered elsewhere. The document length (4993 chars) is substantial enough that it is not just a brief notification of a report being available (RPA).
2024-06-12 English
Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific operational milestone: the successful industrial-scale production transfer of their drug candidate BIO101 by a third-party manufacturer (Seqens). It includes quotes from the CEO, details about the drug's development stage (DMD indication), and forward-looking statements typical of corporate news releases. This is not a comprehensive annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a proxy statement (DEF 14A). Since it is a general announcement of a significant corporate event/update that doesn't fit the highly specific categories like M&A (TAR) or Director's Dealing (DIRS), it best fits the general Regulatory Filings category (RNS) or potentially an Earnings Release (ER) if it were tied to a financial period, but it is primarily operational news. Given the nature of announcing a manufacturing success and clinical trial readiness, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, as it is a standard press release format. However, upon reviewing the definitions, this announcement is a specific update on the development pipeline and manufacturing progress. It is not a formal Earnings Release (ER) which focuses on financial results. It is a general corporate update. RNS is the best fit as a general regulatory announcement/press release that doesn't match other specific types.
2024-06-12 French
Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press release" and announces a specific corporate action: the filing of an Investigational New Drug (IND) application with the US FDA for a clinical study. This type of announcement, detailing regulatory progress, clinical trial plans, and management commentary, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing a significant regulatory step (IND filing) rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), it fits best under the Earnings Release category if it contains key operational/regulatory highlights, or RNS if it's purely informational. Given the context of clinical development updates, ER is often used for major operational milestones, but RNS is the general regulatory fallback. However, the content is a direct announcement of a regulatory submission, which is a key operational update. Since there is no specific category for 'Regulatory Submission Announcement' and it is not a comprehensive financial report, I will evaluate between ER and RNS. ER usually accompanies financial results. Since this is a standalone regulatory/clinical update, RNS (Regulatory Filings) is the most appropriate general category for non-standard, non-financial-report regulatory news, although it contains elements of operational news that might sometimes be bundled with ERs. Given the options, RNS serves as the best fit for a general regulatory/operational press release that doesn't match a more specific financial report type.
2024-06-10 English
Biophytis annonce le dépôt d'une demande d'IND auprès de la FDA pour son étude de phase 2 dans l'obésité
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a specific corporate action: the filing of an Investigational New Drug (IND) application with the FDA for a Phase 2 obesity study. This is a material, non-financial announcement regarding regulatory progress and clinical development. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER), or a Call Transcript (CT). Since it is a specific regulatory/clinical update that doesn't fit the other specialized categories (like M&A, Dividend, Director's Dealing), it falls best under the general 'Regulatory Filings' category (RNS) as a significant, time-sensitive announcement, or potentially a general 'LTR' (Legal Proceedings Report) if the focus was on regulatory hurdles, but RNS is a better fit for general regulatory progress announcements not covered elsewhere. Given the options, RNS serves as the most appropriate catch-all for significant, non-financial, non-presentation regulatory news.
2024-06-10 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.